Oxford Nanopore Technologies plc (ONTTF)
| Market Cap | 1.47B -24.4% |
| Revenue (ttm) | 301.35M +22.2% |
| Net Income | -195.42M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,300 |
| Open | 1.540 |
| Previous Close | 1.530 |
| Day's Range | 1.500 - 1.554 |
| 52-Week Range | 1.270 - 3.340 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About ONTTF
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a ... [Read more]
Financial Performance
In 2025, ONTTF's revenue was 223.90 million, an increase of 22.22% compared to the previous year's 183.20 million. Losses were -145.20 million, -0.68% less than in 2024.
Financial numbers in GBP Financial StatementsNews
Oxford Nanopore Technologies Earnings release: H1 2026
Oxford Nanopore Technologies released its H1 2026 earnings on July 13, 2026, summarizing the period's financial results.
Oxford Nanopore price target lowered to 220 GBp from 240 GBp at Citi
Citi analyst Veronika Dubajova lowered the firm’s price target on Oxford Nanopore (ONTTF) to 220 GBp from 240 GBp and keeps a Buy rating on the shares. Published first on…
Oxford Nanopore price target raised to 172 GBp from 170 GBp at Barclays
Barclays raised the firm’s price target on Oxford Nanopore (ONTTF) to 172 GBp from 170 GBp and keeps an Overweight rating on the shares. The firm sees the company’s’ reduced…
Oxford Nanopore price target lowered to 225 GBp from 300 GBp at RBC Capital
RBC Capital analyst Charles Weston lowered the firm’s price target on Oxford Nanopore (ONTTF) to 225 GBp from 300 GBp and keeps an Outperform rating on the shares. Published first…
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
OXFORD, England & TOKYO--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations...
Oxford Nanopore Technologies Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue growth is strong in clinical and applied industrial markets, with rapid adoption in rare disease, infectious disease, and oncology. Technology differentiation, strategic partnerships, and biopharma applications are driving expansion, while financial targets have been adjusted to reflect market and execution challenges.
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's f...
Oxford Nanopore price target lowered to 230 GBp from 250 GBp at Berenberg
Berenberg analyst Sam England lowered the firm’s price target on Oxford Nanopore (ONTTF) to 230 GBp from 250 GBp and keeps a Buy rating on the shares. Published first on…
Oxford Nanopore Technologies Earnings Call Transcript: H2 2025
FY 2025 saw 24% revenue growth, margin expansion, and improved EBITDA loss, driven by strong applied market performance and disciplined cost control. FY 2026 guidance targets 21–25% revenue growth, 62% gross margin, and continued operational leverage, with breakeven EBITDA expected in 2027.
Oxford Nanopore Technologies Annual report: H2 2025
Oxford Nanopore Technologies has published its H2 2025 annual report on March 2, 2026.
Oxford Nanopore Technologies Slides: H2 2025
Oxford Nanopore Technologies has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 2, 2026.
Oxford Nanopore Technologies Annual report: H2 2025
Oxford Nanopore Technologies has published its H2 2025 annual report on March 2, 2026.
Oxford Nanopore price target raised to 300 GBp from 280 GBp at RBC Capital
RBC Capital raised the firm’s price target on Oxford Nanopore (ONTTF) to 300 GBp from 280 GBp and keeps an Outperform rating on the shares.
Oxford Nanopore Technologies Transcript: Fireside Chat
Revenue and cash performance exceeded expectations, driven by strong growth in clinical and biopharma segments, a shift to a CapEx model, and ongoing innovation. Despite regional and execution challenges, the outlook remains positive with ambitious financial targets and new product launches expected to drive future growth.
Oxford Nanopore Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust financial growth, platform innovation, and expanding clinical and biopharma applications. Strategic partnerships, a shift to a CAPEX model, and operational scalability underpin confidence in meeting 2027 profitability targets and continued market share gains.
Oxford Nanopore Technologies Slides: 44th Annual J.P. Morgan Healthcare Conference
Oxford Nanopore Technologies has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Oxford Nanopore Technologies Earnings release: H2 2025
Oxford Nanopore Technologies released its H2 2025 earnings on January 12, 2026, summarizing the period's financial results.
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company's first IVD device registered in t...
Oxford Nanopore upgraded to Hold from Sell at Stifel
Stifel upgraded Oxford Nanopore (ONTTF) to Hold from Sell with a price target of 140 GBp, up from 120 GBp.
Oxford Nanopore Technologies Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership transition is underway with a focus on biopharma and clinical growth, targeting EBITDA break-even by 2027. Technology differentiation and strong execution have driven top-end revenue guidance, with new pricing models and partnerships supporting margin and market expansion. Biopharma QC and clinical segments are key growth drivers.
Oxford Nanopore Technologies Transcript: Citi Annual Global Healthcare Conference 2025
Upgraded 2025 guidance reflects strong growth in the Americas and clinical/biopharma sectors, with major contracts like UK Biobank set to drive 2026 revenue. Pricing and business model changes have improved margins and cash flow, while operational focus shifts to high-value segments and leadership transitions support future scalability.
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--At the American Society of Human Genetics (ASHG) 2025 industry session on 16th October, Oxford Nanopore Technologies will share its latest developments in...
Oxford Nanopore Technologies Earnings Call Transcript: H1 2025
Revenue grew 28% constant currency in H1 2025, with strong gains across all segments and regions. Gross margin reached 58.2% (61% excluding a one-off charge), and adjusted EBITDA loss improved 22% year-on-year. Guidance for 2025 is reaffirmed, with a focus on high-priority applied and clinical markets.
Oxford Nanopore Technologies Earnings release: H1 2025
Oxford Nanopore Technologies released its H1 2025 earnings on September 2, 2025, summarizing the period's financial results.
Oxford Nanopore Technologies Slides: H1 2025
Oxford Nanopore Technologies has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 2, 2025.